The Fall 2023 Impact Report is a showcase of inspiring stories, groundbreaking research, and transformative progress made possible by your unwavering support. In it, you’ll read about:
Making inroads in research to block inflammation and heal the intestine.
Leading a definitive study on the prevalence of IBD in the U.S.
Bringing recipes from our Gut-Friendly Recipe Finder to patients through online cooking classes.
Helping patients learn about the new biosimilar medications available in 2023.
Publishing a study on the life-changing impact of Camp Oasis, our sleepaway camp for kids with IBD.
Foundation Joins Forces with Mark Cuban Cost Plus Drugs to Improve Medication Access to Patients
The Foundation is joining forces with the Mark Cuban Cost Plus Drug Company(Cost Plus Drugs) to increase awareness of opportunities for accessing some reduced-price essential IBD medications. Cost Plus Drugs currently offers several medications that treat Crohn’s disease and ulcerative colitis at a significantly lower cost than other pharmacies. For example, Cost Plus Drugs offersYusimry™ (adalimumab-aqvh), a biosimilar of HUMIRA®, at $584, compared with a list price of $995 at other pharmacies.
As a public-benefit corporation — a corporation created to generate social and public good, operating in a responsible and sustainable manner — Cost Plus Drugs’ mission is to radically reduce the cost of prescription drugs for patients.
Your generous donation today fuels a brighter tomorrow for IBD patients. Join us in making a collective impact in the fight against Crohn’s disease and ulcerative colitis!
Support the Northern California Chapter and make an impact in the fight against IBD today!
Join our volunteer Joshua Bradley at four exciting events to benefit the Foundation.Read moreabout why Joshua is inspired to fundraise with his running community here and help him reach his goal of raising $5,000!
An Evening with an Autoimmune Athlete - book signing and Q&A
